These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 7648765)

  • 1. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
    Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T
    Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status.
    Yasuda S; Horai Y; Tomono Y; Nakai H; Yamato C; Manabe K; Kobayashi K; Chiba K; Ishizaki T
    Clin Pharmacol Ther; 1995 Aug; 58(2):143-54. PubMed ID: 7648764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
    Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
    Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
    Sohn DR; Kwon JT; Kim HK; Ishizaki T
    Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
    Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
    Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
    Tybring G; Böttiger Y; Widén J; Bertilsson L
    Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.
    Rost KL; Brösicke H; Brockmöller J; Scheffler M; Helge H; Roots I
    Clin Pharmacol Ther; 1992 Aug; 52(2):170-80. PubMed ID: 1505152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.
    Böttiger Y; Tybring G; Götharson E; Bertilsson L
    Clin Pharmacol Ther; 1997 Oct; 62(4):384-91. PubMed ID: 9357389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
    Yu KS; Yim DS; Cho JY; Park SS; Park JY; Lee KH; Jang IJ; Yi SY; Bae KS; Shin SG
    Clin Pharmacol Ther; 2001 Apr; 69(4):266-73. PubMed ID: 11309556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.
    Sohn DR; Kusaka M; Ishizaki T; Shin SG; Jang IJ; Shin JG; Chiba K
    Clin Pharmacol Ther; 1992 Aug; 52(2):160-9. PubMed ID: 1505151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
    Lin CJ; Yang JC; Uang YS; Chern HD; Wang TH
    Pharmacotherapy; 2003 Jun; 23(6):711-9. PubMed ID: 12820812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
    Rost KL; Brockmöller J; Esdorn F; Roots I
    J Hepatol; 1995 Sep; 23(3):268-77. PubMed ID: 8550990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin.
    Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Ishizaki T
    Clin Pharmacol Ther; 2001 Mar; 69(3):108-13. PubMed ID: 11240974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
    Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
    Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
    Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
    Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
    Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.
    Partovian C; Jacqz-Aigrain E; Keundjian A; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1995 Sep; 58(3):257-63. PubMed ID: 7554698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.